How have endo/endo-like offices been performing since ESS took them over? In the territories where i have spoken to reps(CA-Fresno,SJ,SF,SC,LA,LA-south), market share has plummeted to the low 10's and 20's with farxiga, Onglyza and Bydureon. Has this been happening in other territories across the nation? Its pretty embarrassing, but ESS wont let us touch the Endos with a 10ft pole....
If you looked, you'd see another similar thread with 300 posts. I think you'll find your answer there, and more.
This cluster f won't last the year. Layoffs.....have to ....which means assimilating ESS back into primary care type territories and booting the one's AZ management decides upon. Huge dogfight between ESS managers and PC managers. Who stays? Who goes? Uglier than it is now.
Here's the problem. AZ top brass has got to quit changing stuff. Just because you want to put something on your SCORECARD, doesn't mean it's the right thing. I have a feeling diabetes is going to get their asses handed to them this year with the brilliant changes that were made.
